ZEMPLAR
Drug
AbbVie Inc.
Total Payments
$532,945
Transactions
99
Doctors
4
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $156,328 | 37 | 4 |
| 2023 | $90,927 | 33 | 0 |
| 2022 | $118,015 | 18 | 0 |
| 2021 | $104,152 | 8 | 0 |
| 2020 | $63,523 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $531,545 | 95 | 99.7% |
| Consulting Fee | $1,400 | 4 | 0.3% |
Payments by Type
Research
$531,545
95 transactions
General
$1,400
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) | ABBVIE INC. | $239,344 | 0 |
| A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis | ABBVIE INC. | $104,152 | 0 |
| A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) | ABBVIE INC. | $90,995 | 0 |
| M11-617 | AbbVie Inc. | $63,523 | 0 |
| Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $28,080 | 0 |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | ABBVIE INC. | $5,451 | 0 |
Top Doctors Receiving Payments for ZEMPLAR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $531,545 | 95 |
| , PNP | Pediatrics | New Hyde Park, NY | $350.00 | 1 |
| , FNP-BC | Family | Joliet, IL | $350.00 | 1 |
| , ACNP-CS, MS, RN | Acute Care | Albany, NY | $350.00 | 1 |
| , APRN | Pediatrics | Boston, MA | $350.00 | 1 |
Ad
Manufacturing Companies
- ABBVIE INC. $469,422
- AbbVie Inc. $63,523
Product Information
- Type Drug
- Total Payments $532,945
- Total Doctors 4
- Transactions 99
About ZEMPLAR
ZEMPLAR is a drug associated with $532,945 in payments to 4 healthcare providers, recorded across 99 transactions in the CMS Open Payments database. The primary manufacturer is AbbVie Inc..
Payment data is available from 2020 to 2024. In 2024, $156,328 was paid across 37 transactions to 4 doctors.
The most common payment nature for ZEMPLAR is "Unspecified" ($531,545, 99.7% of total).
ZEMPLAR is associated with 6 research studies, including "A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)" ($239,344).